Quanterix (QTRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
The annual meeting will be held virtually on June 9, 2026, with voting on key proposals including director elections, executive compensation, auditor ratification, and an equity plan amendment.
Only stockholders of record as of April 14, 2026, are eligible to vote, with multiple voting methods available.
The Board recommends voting in favor of all proposals and nominees.
Voting matters and shareholder proposals
Stockholders will vote to elect two directors for one-year terms, approve executive compensation (say-on-pay), ratify KPMG LLP as auditor, and approve the amended 2017 Equity Incentive Plan.
Majority of votes cast is required for approval of each proposal; broker discretionary voting is only permitted for auditor ratification.
Shareholder proposals and director nominations for the 2027 meeting must follow specific deadlines and procedures.
Board of directors and corporate governance
The Board consists of nine members, with a transition to annual elections for all directors by 2028.
Board committees include Audit, Compensation, and Nominating and Governance, each with defined responsibilities and independent membership.
Board leadership includes a Chair and a Lead Independent Director, with annual self-evaluations and robust governance guidelines.
Stock ownership guidelines apply to directors and executives to align interests with shareholders.
Latest events from Quanterix
- Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024.QTRX
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 34% YoY, but guidance cut and breakeven delayed amid execution and market headwinds.QTRX
Q2 2026 - Blood-based diagnostics gain momentum as early detection and monitoring become central to Alzheimer's care.QTRX
Goldman Sachs 45th Annual Global Healthcare Conference - Diagnostics expansion and innovation set to drive growth and cash flow breakeven in H2.QTRX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Proxy supplement updates equity plan limits and confirms key votes for the 2026 annual meeting.QTRX
Proxy filing - Q1 2026 revenue up 20% to $36.4M, with improved margins and $85M in cost synergies.QTRX
Q1 2026 - Diagnostics and diversification drive growth as financial discipline and innovation strengthen outlook.QTRX
Leerink Global Healthcare Conference 2026 - Q3 2024 revenue rose 13% to $35.8M; guidance reaffirmed and Emission Inc. acquisition announced.QTRX
Q3 2024 - Record consumables and cost cuts offset revenue decline as Akoya merger and Simoa ONE advance.QTRX
Q1 2025